文献速递肝病消化道肿瘤与早癌

FGF19上调SOX18通过反式激活FGFR4和FLT4促进肝细胞癌转移

Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4.
PubMed 文献 · Hepatology · 2020-02-10

本研究探讨SOX18在肝细胞癌(HCC)转移中的作用及FGF19-SOX18-FGFR4正反馈环路。SOX18高表达与HCC低分化、高TNM分期及不良预后正相关;SOX18通过上调FGFR4和FLT4促进转移,而FGF19-FGFR4通路经p-FRS2/p-GSK3β/β-catenin上调SOX18,形成正反馈;FGFR4抑制剂BLU9931可显著减少SOX18介导的侵袭和转移。

要点

  • SOX18高表达与HCC低分化、高TNM分期及不良预后正相关。
  • SOX18通过上调FGFR4和FLT4促进HCC侵袭和转移。
  • FGF19-SOX18-FGFR4正反馈环路驱动HCC转移,BLU9931可抑制。

核心结论

  • FGF19-SOX18-FGFR4正反馈环路在HCC转移中起关键作用,靶向该通路可能是HCC临床管理的有前景的治疗选择。

研究设计与样本

  • 本文为基础与转化研究,涉及HCC细胞实验、人类HCC组织分析及分子机制探讨,具体样本量未在摘要中报告。

主要发现

  • SOX18表达升高与HCC低分化、较高TNM分期及不良预后正相关。
  • SOX18过表达通过上调FGFR4和FLT4促进HCC转移。
  • 同时敲低FGFR4和FLT4显著减少SOX18介导的HCC侵袭和转移,而稳定过表达FGFR4和FLT4可逆转抑制SOX18所致的侵袭和转移下降。
  • FGF19作为FGFR4配体上调SOX18表达,该上调依赖p-FRS2/p-GSK3β/β-catenin通路。
  • 敲低SOX18显著减少FGF19增强的HCC侵袭和转移;BLU9931显著减少SOX18介导的HCC侵袭和转移。

临床怎么用

  • SOX18高表达及与FGF19、FGFR4、FLT4共表达可能作为HCC预后评估的参考指标。
  • FGFR4特异性抑制剂BLU9931在实验研究中显著减少SOX18介导的HCC侵袭和转移,提示靶向FGF19-SOX18-FGFR4环路可能是HCC治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The poor prognosis of patients with hepatocellular carcinoma (HCC) is mainly attributed to its high rate of metastasis and recurrence. However, the molecular mechanisms underlying HCC metastasis need to be elucidated. The SRY-related high-mobility group box (SOX) family proteins, which are a group of highly conserved transcription factors, play important roles in cancer initiation and progression. Here, we report on a role of SOX18, a member of the SOX family, in promoting HCC invasion and metastasis. APPROACH AND RESULTS: The elevated expression of SOX18 was positively correlated with poor tumor differentiation, higher tumor-node-metastasis (TNM) stage, and poor prognosis. Overexpression of SOX18 promoted HCC metastasis by up-regulating metastasis-related genes, including fibroblast growth factor receptor 4 (FGFR4) and fms-related tyrosine kinase 4 (FLT4). Knockdown of both FGFR4 and FLT4 significantly decreased SOX18-mediated HCC invasion and metastasis, whereas the stable overexpression of FGFR4 and FLT4 reversed the decrease in cell invasion and metastasis that was induced by inhibition of SOX18. Fibroblast growth factor 19 (FGF19), which is the ligand of FGFR4, up-regulated SOX18 expression. A mechanistic investigation indicated that the up-regulation of SOX18 that was mediated by the FGF19-FGFR4 pathway relied on the phosphorylated (p)-fibroblast growth factor receptor substrate 2/p-glycogen synthase kinase 3 beta/β-catenin pathway. SOX18 knockdown significantly reduced FGF19-enhanced HCC invasion and metastasis. Furthermore, BLU9931, a specific FGFR4 inhibitor, significantly reduced SOX18-mediated HCC invasion and metastasis. In human HCC tissues, SOX18 expression was positively correlated with FGF19, FGFR4, and FLT4 expression, and patients that coexpressed FGF19/SOX18, SOX18/FGFR4, or SOX18/FLT4 had the worst prognosis. CONCLUSIONS: We defined a FGF19-SOX18-FGFR4 positive feedback loop that played a pivotal role in HCC metastasis, and targeting this pathway may be a promising therapeutic option for the clinical management of HCC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Chen J, Du F, Dang Y, et al. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4. Hepatology. 2020. PMID: 31529503. doi:10.1002/hep.30951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。